SEC Form 4 · accession 0001209191-16-134000
INNOVATE BIOPHARMACEUTICALS, INC. · INNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jawahar Tandon
Officer — Chairman of the Board · Director
Period of report
Jul 7, 2016
Accepted (ET)
Jul 26, 2016 · 7:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551986
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 7, 2016 | A | 125,000 | $0.00 | A | 125,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to Purchase Common StockF2,F3 | $5.625 | Jul 7, 2016 | A | 76,911 | A | Jul 7, 2017 | Jul 7, 2021 | Common Stock | 76,911 | 76,911 | I |
Explanation of responses
- F1Shares of restricted common stock granted under Issuer's 2012 Omnibus Incentive Plan. Such shares are subject to a lock-up agreement until one year after the grant date.
- F2Warrants issued pursuant to the conversion of certain debt as described in Issuer's Registration Statement on Form S-1, as amended (Registration No. 333-207938).
- F3Warrants to purchase common stock of Issuer ("Warrants") issued to Tandon Enterprises, Inc., a corporation controlled by Reporting Person and his brother. The Reporting Person disclaims beneficial ownership of the Warrants, and the underlying shares of common stock issuable upon exercise thereof, except to the extent of his pecuniary interest, if any, therein.